Dr Teresa Macarulla talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about results from the phase III POLO trial - which assessed the use of olaparib as a maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA1/2 mutation and metastatic pancreatic cancer, compared with a placebo.
Dr Macarulla mentions that progression-free survival was the primary endpoint of this trial, along with overall survival, response rate, quality of life and adverse events were also assessed.
She emphasises the importance of this trial, which is the first positive study in this setting and offers a novel treatment option with patients with metastatic pancreatic cancer.
Dr Macarulla also believes patients should be tested routinely for BRCA1/2 mutations, to identify the 7-8% of patients that could benefit from this treatment.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.